These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29686421)

  • 21. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients.
    Sarasquete ME; Gutiérrez NC; Misiewicz-Krzeminska I; Paiva B; Chillón MC; Alcoceba M; García-Sanz R; Hernández JM; González M; San-Miguel JF
    Haematologica; 2011 Mar; 96(3):468-71. PubMed ID: 21160068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.
    Mikulasova A; Smetana J; Wayhelova M; Janyskova H; Sandecka V; Kufova Z; Almasi M; Jarkovsky J; Gregora E; Kessler P; Wrobel M; Walker BA; Wardell CP; Morgan GJ; Hajek R; Kuglik P
    Eur J Haematol; 2016 Dec; 97(6):568-575. PubMed ID: 27157252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
    Avet-Loiseau H; Attal M; Campion L; Caillot D; Hulin C; Marit G; Stoppa AM; Voillat L; Wetterwald M; Pegourie B; Voog E; Tiab M; Banos A; Jaubert J; Bouscary D; Macro M; Kolb B; Traulle C; Mathiot C; Magrangeas F; Minvielle S; Facon T; Moreau P
    J Clin Oncol; 2012 Jun; 30(16):1949-52. PubMed ID: 22547600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathogenesis of multiple myeloma.
    Tonon G
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):985-1006, vii. PubMed ID: 17996585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.
    Brousseau M; Leleu X; Gerard J; Gastinne T; Godon A; Genevieve F; Dib M; Lai JL; Facon T; Zandecki M;
    Clin Cancer Res; 2007 Oct; 13(20):6026-31. PubMed ID: 17947464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS.
    Türkmen S; Binder A; Gerlach A; Niehage S; Theodora Melissari M; Inandiklioglu N; Dörken B; Burmeister T
    Genes Chromosomes Cancer; 2014 Aug; 53(8):650-6. PubMed ID: 24729354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chromosomal abnormalities and clonal evolution in multiple myeloma].
    Ishida T
    Rinsho Ketsueki; 2014 Oct; 55(10):2036-45. PubMed ID: 25297769
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cytogenetic study of multiple myeloma].
    Zhang Y; Jiang B; Huang XJ; Shi Y; He Q; Dang H; Qiu JY; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):76-8. PubMed ID: 17490526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.
    Dutta AK; Alberge JB; Sklavenitis-Pistofidis R; Lightbody ED; Getz G; Ghobrial IM
    Nat Rev Clin Oncol; 2022 Apr; 19(4):223-236. PubMed ID: 35017721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
    J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cytogenetic and molecular basis of multiple myeloma].
    Taniwaki M; Matsumoto Y
    Nihon Rinsho; 2007 Dec; 65(12):2179-86. PubMed ID: 18069258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.
    Smadja NV; Leroux D; Soulier J; Dumont S; Arnould C; Taviaux S; Taillemite JL; Bastard C
    Genes Chromosomes Cancer; 2003 Nov; 38(3):234-9. PubMed ID: 14506697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
    López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
    Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level.
    Nagy Z; Kajtár B; Jáksó P; Dávid M; Kosztolányi S; Hermesz J; Kereskai L; Pajor L; Alpár D
    Leuk Res; 2011 Aug; 35(8):1114-6. PubMed ID: 21377730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.